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The final selection included 16 studies. Overall, those studies 
indicate that conditioning of immunosuppression, condi-
tioning of allergic responses, and conditioning of insulin and 
glycemic responses is possible. Regarding immuno-
stimulants, antiallergic effects, and cortisol conditioning, the 
preliminary results are promising, but additional studies are 
needed.  Conclusions: This systematic review shows classical 
conditioning of immune and endocrine responses for vari-
ous pharmaceutical substances. The studies reviewed here 
indicate that the number of acquisition and evocation ses-
sions, and characteristics of the unconditioned and condi-
tioned stimuli, are important determinants of the effective-
ness of pharmacological conditioning on immune and endo-
crine parameters. In the future, conditioned pharmacological 
effects may be used clinically as adjunct therapy in various 
patient populations.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Keywords 
 Pharmacological conditioning · Associative learning · 
Placebo effect · Placebo · Endocrine system · Immune 
system · Allergy  
 Abstract 
 Background: Conditioned pharmacological effects may 
provide relevant clinical opportunities to improve treatment 
for patients with a variety of conditions. The aim of this sys-
tematic review was to create an overview of studies in this 
field of research and to investigate whether specific charac-
teristics of the study design make for successful condition-
ing.  Methods: The protocol of this review was registered in 
Prospero (PROSPERO 2015: CRD42015024148). A systematic 
literature search was conducted in the databases PubMed, 
Embase, and PsychInfo. Studies were included if they were 
placebo-controlled trials in humans in which the effects of a 
pharmacological agent on immune or endocrine outcomes 
(e.g., interleukin-2 and cortisol) were conditioned, using a 
specific conditioned stimulus. The risk of bias of each study 
was assessed using the Cochrane risk-of-bias tool.  Results: 
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 Learning about associations between external and in-
ternal stimuli is of high adaptive value for the survival of 
any animal  [1] . One mechanism by which these associa-
tions are learned is Pavlovian or classical conditioning. 
Classical conditioning is an associative learning process 
about the temporal and causal relationships of specific 
stimuli, and it is used to modify behavior, cognitions, and 
physiological reactions. In the past decades, evidence has 
also been found for conditioning of physiological re-
sponses of the immune and endocrine systems  [2, 3] . 
Conditioning of physiological functions, such as immune 
and endocrine parameters, can be achieved when the pre-
sentation of a conditioned stimulus (CS) is repeatedly 
paired with the administration of an unconditioned stim-
ulus (UCS). The UCS is mostly a pharmacological agent 
with specific physiological actions (unconditioned re-
sponse; UCR). After several paired administrations of CS 
and UCS during the acquisition phase, in the evocation 
phase administration of the CS alone is enough to trigger 
changes in the body (conditioned response; CR) often 
similar to the changes caused by the pharmacological 
UCS  [3] . When a CR is repeatedly evoked by the admin-
istration of a CS without a UCS, extinction occurs by a 
gradually decreasing CR with every evocation.
 That immune and endocrine parameters can be con-
ditioned illustrates a close interaction between the central 
nervous system and peripheral functions regulating ho-
meostasis and therefore has important implications for 
the study of placebo and nocebo effects  [1, 2] . Placebo and 
nocebo effects occur when a patient’s expectations affect 
health outcomes  [4–6] . These expectations can be either 
explicit or implicit. Explicit expectations can be induced 
by, for example, verbal suggestions and affect primarily 
conscious, subjective processes such as pain. Implicit ex-
pectations are thought to be induced primarily by (phar-
macological) conditioning and can affect automatic pro-
cesses such as immune and endocrine parameters  [7] . 
Conditioning of immune and endocrine parameters also 
has important clinical implications  [8–14] . An example 
of this is provided by a study showing that the magnitude 
of conditioned antihistamine effects in participants with 
rhinitis due to house dust mite allergy does not signifi-
cantly differ from direct antihistamine drug effects  [8] . 
When this effect is found to be retainable, this implies that 
patients could reduce the amount of medication needed 
to ameliorate allergic symptoms. Thus, conditioning of 
such parameters could bear relevance for a wide variety 
of issues in medical and psychological sciences  [15] . 
However, a large heterogeneity has been reported in the 
effects found within the field of pharmacological condi-
tioning of immune and endocrine effects  [8, 9] .
 A potentially important explanation for this heteroge-
neity in studies on conditioned pharmacological effects 
lies in differences in the design of studies. Studies to date 
have shown much variability with regard to the number 
of acquisition and evocation trials as well as with regard 
to the nature of the CS and UCS used. However, the rel-
evance of these characteristics for finding conditioned 
pharmacological effects has not yet been systematically 
investigated. Therefore, the aim of this paper is to create 
a systematic overview of the existing studies in this field 
of research and to further elucidate whether there are spe-
cific characteristics of the study design that make success-
ful conditioning of pharmacological effects more likely. 
To achieve this aim, placebo-controlled trials in humans 
addressing pharmacological conditioning (with a phar-
macological agent as the UCS and a specific CS) of im-
mune or endocrine outcomes (e.g., interleukin (IL)-2 and 
cortisol) will be systematically reviewed with regard to 
these design characteristics.
 Methods 
 This review was conducted in accordance with the PRISMA 
statement  [16, 17] . The protocol of this review was registered in 
Prospero (PROSPERO 2015: CRD42015024148).
 Study Criteria and Search Strategy 
 Studies were eligible for inclusion in this review if they met the 
following criteria: (1) the study report was written in English, (2) 
the study was conducted in humans, (3) new data were presented 
in the study, (4) a pharmacological UCS was used, (5) a well-de-
fined CS was used (distinct taste or smell and not an unspecified 
laboratory environment), (6) an immune (e.g., IL-2) or endocrine 
(e.g., cortisol) outcome was assessed, and (7) the study was a pla-
cebo-controlled trial.
 The inclusion criteria were translated into a search term com-
prising Medical Subject Headings (MeSH) and text words (tw) and 
combining conditioning of a pharmacological agent, eligible types 
of outcome measures, and the UCS used. With this search term,
a systematic literature search was conducted in the databases 
PubMed, PsychInfo, and Embase on June 1, 2015. See online sup-
plementary figure 1 (see www.karger.com/doi/10.1159/000449470 
for all online suppl. material) for the search term used for the elec-
tronic search in PubMed. The search terms for Embase and 
PsychInfo were built from this search term. Also, the reference lists 
and citing articles of all of the articles included in this review were 
checked in Web of Science for additional articles meeting the in-
clusion criteria. All of the study titles were screened for thematic 
relevance by one rater. Two independent raters examined the ab-
stracts of relevant studies according to the inclusion criteria. When 
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whether the article fulfilled the inclusion criteria, or if the article 
was deemed eligible by one or both raters, the full text was exam-
ined by both raters. Discrepancies between the two raters were 
resolved by discussion with a third rater.
 Risk-of-Bias Assessment 
 Two independent raters assessed the risk of bias (RoB) of each 
included study using the Cochrane risk-of-bias tool  [18] . Assessed 
biases included selection bias (randomization process and alloca-
tion concealment), performance bias (blinding of participants and 
research personnel), detection bias (blinding of the outcome as-
sessment), reporting bias (handling of missing data), and attrition 
bias (reasons for withdrawal in all conditions). When the two rat-
ers did not reach agreement, a third rater was consulted to reach 
consensus. The RoB was assessed based on the information pro-
vided in the article.
 Parameters Extracted from the Studies 
 Regarding effects and design issues, parameters extracted from 
the papers included the effects of conditioning on immune and 
endocrine parameters, the number of acquisition and evocation 
sessions, the characteristics of the CS and the UCS, and the se-
quence in which the CS and the UCS were presented (i.e., the CS 
was presented preceding or following the UCS). Also information 
about responders and nonresponders to the conditioning proce-
dure and the magnitude of the CR was extracted. Other relevant 
descriptors of the studies included effects of conditioning on self-
reported measures, such as self-reported symptoms, and charac-
teristics of the study population, including age, gender, the num-
ber of participants, and the type of participants (healthy or patient 
samples).
 Results 
 Search Results  
 A total of 12,016 studies were found by searching the 
PubMed, Embase, and PsychInfo databases. After screen-
ing the titles, 153 abstracts remained to be screened by 2 
independent raters. Of these, 30 studies were examined in 
full text. Twelve studies were found to be eligible for in-
clusion in this review. Screening of the reference lists and 
citing articles of the included studies in Web of Science 
yielded another 4 studies eligible for inclusion. The num-
ber of excluded studies and the reasons for exclusion are 
displayed in online supplementary figure 2.
 RoB Analysis 
 The results of the RoB analysis are shown in the RoB 
graph (online suppl. fig. 3) and the RoB summary (online 
suppl. fig. 4). Selection and allocation bias were assessed 
based on the way randomization was achieved and the 
measures taken to conceal the group allocation. Eleven 
studies did not provide information on how randomiza-
tion was achieved and 3 studies did not explicitly state 
that the allocation of participants was done randomly 
(unclear RoB, 88%). One study reported that randomiza-
tion was done by the pharmacy (low RoB, 6%), and one 
study indicated that randomization was based on the se-
quence of inclusion of the participants (high RoB, 6%).
 The RoB due to a lack of blinding of participants and 
personnel (performance bias) was considered to be low 
for 12 studies (75%), given that the outcome measured in 
these studies was biochemical and therefore less likely to 
be influenced by bias. In 3 studies investigating allergic 
patients (19%), administration of the UCS led to either an 
increase or a decrease in allergic symptoms, making com-
plete blinding unlikely. It is, however, unclear whether 
this lack of blinding affected the biochemical outcome of 
the study (unclear RoB). In one study, blinding seemed to 
be highly unlikely due to the extreme effects of the UCS 
(lipopolysaccharide) (high RoB, 6%). Because all of the 
studies included in this review assessed biochemical out-
comes, the risk of detection bias was considered to be low. 
Regarding incomplete outcome data (attrition bias), 9 
studies did not provide enough information to assess the 
RoB (unclear RoB, 56%) and 6 studies reported that the 
dropout rate was equal for the experimental and control 
groups (low RoB, 38%). One study stated that only par-
ticipants who completed all measurements were included 
in the analysis, without reporting the reasons for dropout 
or the allocation of subjects who were lost to attrition 
(high RoB, 6%). Small samples often in combination with 
unequal group sizes were identified as an additional 
source of possible bias in 6 studies (unclear RoB, 38%).
 Conditioning Paradigms 
 Detailed information on the design characteristics of 
the included studies is presented in online supplementary 
table 1. Eleven of the 16 studies were aimed at condition-
ing of immune functions (69%) and 5 studies were aimed 
at conditioning of endocrine functions (31%). Concern-
ing the studies on conditioning of immune functions, 5 
studies addressed conditioned immunosuppression (31% 
of all studies)  [19–23] , 3 studies addressed conditioned 
immunostimulation (19%)  [24–26] , and 3 studies ad-
dressed conditioned allergic responses (19%)  [9, 27, 28] . 
Of the studies on conditioning of endocrine outcomes, 4 
(25%) addressed conditioned glycemic responses  [29–32] 
and the remaining study addressed conditioned cortisol 
(6%)  [33] .
 Regarding the general conditioning paradigm, all but 
one  [26] of the studies (94%)  [9, 19–25, 27–33] employed 
a design with an acquisition phase, in which the UCS was 
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which the CS was presented together with a placebo. The 
remaining study on immunostimulation employed an in-
termittent treatment schedule in which the CS was con-
sistently paired with the UCS in the first phase of the 
study (acquisition phase) and was administered intermit-
tently with or without the UCS in the second phase of the 
study  [26] .
 Sample Characteristics 
 The total sample size of the studies varied between 15 
 [33] and 62  [9] , with 5  [28] to 32  [21] participants per 
group. The participants in 13 studies were healthy volun-
teers (81%)  [19–26, 29–33] , whereas 3 studies (19%) in-
cluded participants who were allergic to either pollen  [27] 
or house dust mites  [9, 28] .
 The age of the participants varied between 18 and 55 
years  [19, 21–23, 26, 28–30, 33] , with the mean age vary-
ing between 19 and 31  [9, 19–23, 25, 29–33] . Two studies 
(13%) did not provide information on the age of the par-
ticipants  [24, 27] . Concerning the gender  of the partici-
pants, 10 studies (63%) included only male participants 
 [19–23, 25, 29, 30, 32, 33] , while 1 study included only 
female participants (6%)  [31] and 3 studies (19%) includ-
ed male as well as female participants  [9, 26, 28] (60% fe-
male  [9, 26] and 76% female  [28] ). The 2 remaining stud-
ies (13%) did not report the gender of the participants  [24, 
27] .
 CR Affecting Immune Parameters 
 Conditioned Immunosuppression 
 All of the details of the studies examining conditioned 
immune responses are described in online supplemen-
tary table 2. In terms of CR, all but 1  [19] of 5 studies on 
conditioned immunosuppression found a significant de-
crease in stimulated IL-2 in vitro release after evocation 
in the conditioned group versus the control group  [20–
23] .
 Acquisition and Evocation Trials. All of the studies 
used 4 acquisition trials  [19–23] . The number of evoca-
tion trials varied between 1 and 14  [19–23] , with the study 
using 1 evocation trial not reporting significant condi-
tioned immunosuppressive responses  [19] . Of the 4 stud-
ies with more than 1 evocation session, 2 provided no 
information regarding the time course of extinction  [20, 
21] . The third study found a significant conditioned re-
duction in IL-2 after 4 evocation trials and again after 4 
more evocation trials, which commenced 11 days later 
 [22] . In the fourth study, using 14 evocation trials, sig-
nificant conditioned immunosuppression was found af-
ter 2 and 4, but not after 14, evocation trials  [23] .
 Conditioned Stimuli. As the CS, a taste stimulus was 
used in all 5 studies  [19–23] . Two studies investigated 
whether conditioned taste avoidance of the CS occurred 
 [21, 22] . One of these found that the taste of the CS was 
rated significantly more negatively by the conditioned 
group compared to the placebo control group  [22] , 
whereas the other found no difference in hedonic taste 
ratings between groups  [21] .
 Unconditioned Stimuli. All of the studies used the im-
munosuppressant drug cyclosporine A (CsA) as the UCS 
 [19–23] . Administration of CsA led to significant de-
creases in IL-2 in all of the studies. None of the studies 
provided information about possible subjectively notice-
able effects of CsA, but one study reported that the group 
receiving CsA scored significantly higher on a side effects 
questionnaire than the group receiving placebo  [23] .
 Conditioned Immunostimulation 
 The 3 studies on conditioned immunostimulation 
 [24–26] all used different UCS and assessed different out-
come measures (see online suppl. table  2). Two of the 
studies found significant conditioned immunostimulat-
ing effects  [24, 26] and one did not  [25] .
 Acquisition and Evocation Trials. Of the 3 studies, 2 
used a design with a distinct acquisition and evocation 
phase  [24, 25] . Of these, the study using 4 acquisition tri-
als found significant conditioned immunostimulating re-
sponses  [24] , whereas the study using 1 acquisition trial 
did not  [25] . The remaining study  [26] used an intermit-
tent treatment design in which the CS was repeatedly 
paired with the UCS before being presented alone in one 
of several evocation trials or again paired with the UCS in 
a ‘booster session’. This study found significant condi-
tioned effects on serum quinolinic acid, neopterin, and 
CD64 expression on monocytes  [26] . None of the 3 stud-
ies provided information about extinction of the CR  [24–
26] . 
 Conditioned Stimuli. All 3 studies used a taste stimulus 
as the CS  [24–26] , which in one case was a sherbet sweet 
that also provided tactile stimulation in the mouth  [24] . 
The CS was administered before the UCS in 2 studies  [24, 
26] and after the UCS in 1 study  [25] . Only 1 study pro-
vided information about the hedonic qualities of the CS 
 [25] . After the first consumption, the CS was perceived 
overall as novel, with a relatively neutral odor and a rath-
er unpleasant taste. After conditioning, the participants 
in the conditioned group rated the odor of the CS as sig-
nificantly less pleasant than did the participants in the 
control group, while no conditioned effects on cytokine 
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 Unconditioned Stimuli. All 3 studies used different 
UCS. In all of the studies, administration of the UCS led 
to immunostimulatory responses on immune parame-
ters, but only one study reported subjectively noticeable 
symptoms elicited by the UCS  [25] . Additionally, in one 
study, 6 of the total 37 participants (16%) dropped out for 
reasons including low energy levels, dizziness, blurred vi-
sion, acute abdominal pain, and joint pain  [26] , which 
may reflect side effects of UCS administration.
 Conditioned Allergic Responses 
 Three studies investigated conditioned allergic or an-
tiallergic effects in participants who were allergic to either 
pollen  [27] or house dust mites  [9, 28] . Both studies aimed 
at allergic effects by conditioning with allergens found 
significant conditioned effects in immune parameters 
linked to allergic reactions, but not in allergic symptoms 
 [27, 28] ; however, one study found a significant decrease 
in the peak nasal inspiratory airflow  [27] . The remaining 
study was aimed at conditioning antiallergic effects and 
found significant reductions in allergic parameters as well 
as symptoms in both the conditioned and the placebo 
control groups compared to a natural-history group, but 
no significant differences were found between the condi-
tioned and placebo control groups  [9] .
 Acquisition and Evocation Trials. Both studies aimed 
at conditioning allergic effects used 1 acquisition trial and 
1  [28] or 2  [27] evocation trials. Regarding extinction, 
smaller conditioned effects were found in the second 
compared to the first evocation trial  [27] . The study con-
ditioning antiallergic effects used 5 acquisition and 5 evo-
cation trials. After the first evocation, significantly de-
creased wheal sizes and allergic symptom scores were 
found in both the conditioned and the placebo control 
groups when compared to a natural-history group. After 
the fifth evocation, a significant reduction in symptoms 
but not in wheal size was found in both groups compared 
to the natural-history group  [9] , possibly indicating ef-
fects of extinction.
 Conditioned Stimuli. Of the 2 studies conditioning al-
lergic responses, 1 used an odor stimulus  [27] and the 
other used a taste stimulus  [28] as the CS. In both studies, 
the CS was administered before presentation of the UCS. 
No subjective ratings of the hedonic quality of the CS 
were reported. In the study aimed at conditioning antial-
lergic effects, the same CS (drink) as in the studies on 
conditioning of immunosuppressive effects was used 
and administered together with the UCS  [9] . Here, too, 
no data on the subjective quality of the CS were reported 
 [9] .
 Unconditioned Stimuli. Both of the studies condition-
ing allergic effects used intranasally administered aller-
gens as the UCS, which led to an increase in allergic pa-
rameters and allergic symptoms  [27, 28] . The study aimed 
at conditioning antiallergic effects used an antihistamin-
ergic agent as the UCS, leading to significant decreases in 
allergic parameters and symptoms. In that study, symp-
tom scores were also significantly lower in the placebo 
control group than in the natural-history group  [9] .
 CR Affecting Endocrine Parameters 
 All of the details regarding the studies examining con-
ditioned endocrine responses are described in online sup-
plementary table 2. Among the 5 studies addressing con-
ditioning of endocrine functions  [29–33] , 4 studies inves-
tigated conditioned changes in glycemic levels  [29–32] . 
Of the 4 studies, 2  [29, 30] found significant conditioned 
cumulative glycemic decreases from baseline. In one of 
these studies, a second experimental group was examined 
with glucose injection instead of insulin as the UCS, and 
a significant conditioned decrease in the concentration of 
serum insulin, but no effect on glycemia, was found  [30] . 
Two other studies reported a significant conditioned in-
crease in insulin blood levels but no effect on glycemia 
 [31, 32] , C-peptide, or leptin  [31] . The remaining study 
addressed conditioning of plasma cortisol levels as the 
primary outcome measure  [33] . A significant effect indi-
cated an increased cortisol response in the evocation 
phase for the conditioned group versus the placebo group, 
but the results of post hoc analyses were nonsignificant 
 [33] .
 Acquisition and Evocation Trials. Of the 4 studies in-
vestigating conditioned changes in glycemia  [29–31] , the 
studies using 4 acquisition trials and 1 evocation trial 
found significant conditioned effects on glycemia  [29, 30] 
and a significant conditioned decrease in the serum insu-
lin concentration in an additional experimental group re-
ceiving glucose as the UCS  [30] . The remaining 2 studies 
used 6 acquisition trials and 1  [31] or 6 (in 1 day) evoca-
tion trials  [32] . Of these, one used intranasal insulin as the 
CS, and a significant conditioned increase in insulin lev-
els, but no effect on glycemia, was found  [32] . In the re-
maining study, using orally administered glucose as the 
UCS, no conditioned effects were found  [31] . The study 
aimed at conditioning cortisol used 3 acquisition trials 
and 1 evocation trial  [33] . In that study, an overall in-
creased cortisol response was found, but post hoc analy-
ses were nonsignificant  [33] . None of the studies on con-
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 Conditioned Stimuli. In all 4 studies addressing condi-
tioned glycemic effects, an odor was used as the CS  [29–
32] . In 1 of these, the odor was combined with a taste 
stimulus  [31] . In 2 studies, the CS was presented both 
before and during administration of the UCS  [29, 30] ; in 
one study administration of the CS preceded that of the 
UCS  [31] , and in the remaining study the CS cooccurred 
with the UCS  [32] . None of the studies reported subjec-
tive ratings of the hedonic qualities of the CS. In the study 
aimed at conditioning cortisol levels, a taste administered 
before the UCS was used as the CS. Data on the hedonic 
ratings of the CS were not reported, but the authors stat-
ed that no indications for conditioned taste aversion were 
found  [33] .
 Unconditioned Stimuli. In both studies using insulin as 
the UCS, administration led to a direct decrease in blood 
glucose levels, which significantly affected counterregula-
tory hormones and led to an increase in the number of 
neuroglucopenic symptoms  [29, 30] . In the second ex-
perimental group in which glucose was administered as 
the UCS  [30] , a significant increase in insulin and signif-
icant changes in the counterregulatory hormones gluca-
gon and, to a lesser extent, norepinephrine were found 
 [30] . In the third study using insulin as the UCS, the in-
sulin was administered intranasally. This led to an imme-
diate significant increase in peripheral insulin and a sig-
nificant decrease in glycemia that remained within the 
euglycemic range  [32] . Significant changes in epineph-
rine, but not in leptin, norepinephrine, or cortisol, were 
found  [32] . In the study using glucose as the UCS, direct 
effects of UCS administration were not assessed  [31] . The 
study aimed at conditioned effects on cortisol used dexa-
methasone as the UCS, of which the direct effects were 
not reported by the authors  [33] .
 Responders and Nonresponders 
 Of the 16 studies included in this review, 2 (13%) ana-
lyzed samples for responders and nonresponders to the 
conditioning protocol  [21, 29] . In the first study on con-
ditioned immunosuppression by CsA, participants who 
showed a conditioned IL-2 decrease larger than 1 SD were 
categorized as responders. The ratio of responders to 
nonresponders was 15: 17. Responders could be distin-
guished from nonresponders by higher levels of state anx-
iety and plasma norepinephrine at baseline, accounting 
for 60% of the variance  [21] . In the second study on con-
ditioning effects of insulin  [29] , responders were identi-
fied by a median split on the basis of the maximum gly-
cemic decrease shown as a CR during evocation. This 
study found that responders had previously shown a larg-
er UCR after insulin injection on glycemia and had re-
ported significantly more neuroglycopenic symptoms 
caused by the insulin UCS during acquisition. Also, they 
rated the CS (an odor) as significantly more intense than 
nonresponders  [29] . In contrast to the other study  [21] , 
responders had significantly lower baseline norepineph-
rine levels than nonresponders  [21, 29] .
 Magnitude of the CR 
 Four studies (25%) provided explicit information 
about the magnitude of the CR  [21, 27–29] . In one study 
using CsA as the UCS, the conditioned immunosuppres-
sive response was about 40% of the immunosuppression 
caused directly by the UCS  [21] . The conditioned effects 
in responders (defined as participants who showed a con-
ditioned IL-2 decrease larger than 1 SD) were as pro-
nounced as the UCR  [21] . In a second study, addressing 
the conditioned effects of insulin, the conditioned de-
crease in glycemia was 10–15% of the glycemic decrease 
caused by insulin administration during acquisition  [29] . 
The 2 remaining studies investigated conditioned allergic 
responses and found a CR about one third of the size of 
the UCR  [27, 28] .
 Discussion 
 Conditioning of immune and endocrine parameters in 
humans offers new insights into the interaction of the 
central nervous system with peripheral functions, with 
promising possibilities for future adjunct therapies in a 
variety of diseases  [8–14] . Based on the studies reviewed 
here, there is relatively strong evidence that conditioning 
of immunosuppression using CsA  [19–23] , conditioning 
of allergic responses using allergens  [27, 28] , and condi-
tioning of insulin and glycemic responses using intrave-
nous insulin  [29, 30, 32, 34] is possible. Regarding immu-
nostimulants, antiallergic effects, and cortisol condition-
ing, the results look promising, but additional studies are 
needed to support evidence for the effectiveness of differ-
ent UCS  [9, 24–26, 33] . An important strength of this re-
view lies in its systematic approach, offering a detailed 
overview of the existing studies in this field of research. 
To our knowledge, this is the first systematic review of 
studies on conditioning of pharmacological effects on im-
mune and endocrine parameters in humans, specifically 
addressing the current knowledge on the influence of de-
sign characteristics on the effects of pharmacological con-
ditioning. Also, this review includes studies in different 
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for all future studies in conditioned pharmacological ef-
fects. However, the large heterogeneity, in combination 
with the small number of studies included in this review, 
makes it difficult to draw firm conclusions. Most of the 
studies included in this review used relatively small sam-
ples of healthy volunteers, limiting the reliability and gen-
eralizability of the studies on an individual level. Togeth-
er with the small sample sizes reported by some studies, 
this might point to a possible publication bias. Concern-
ing risks for other biases, due to incomplete reporting of 
the study protocol in many of the study reports included 
in this review, the risks of selection, reporting, and attri-
tion bias were unclear for many studies. For the UCS CsA, 
allergens, and insulin, however, conditioned effects have 
been replicated at least once  [19–23, 27–30, 32] , strength-
ening the conclusion that the effects of these UCS can be 
conditioned. Overall, the rigor in study selection, espe-
cially with regard to methodological aspects, might have 
led to the exclusion of some studies in patient samples 
(e.g., inclusion of a placebo control group might be chal-
lenging in patients). However, this same rigor in study 
selection has the important advantage that the studies in-
cluded in this review adhered to a relatively high scien-
tific standard, making the conclusions drawn from these 
studies more reliable.
 As previous research has indicated that the character-
istics of the study design might have an effect on condi-
tioning  [19, 27] , studies were reviewed in light of the de-
sign that was used, providing some potentially important 
considerations for future studies. The studies reviewed in 
this paper suggest that the number of acquisition and evo-
cation trials needed in order to obtain a CR depend on the 
nature of the UCS and the outcome measure targeted for 
a CR. Generally, most consistent conditioned effects were 
found in studies using more than one acquisition trial. 
However, single trial conditioning (only one acquisition 
trial) was found to be sufficient to condition allergic re-
sponses  [27, 28] , but not immunostimulation  [25, 35] . An 
explanation for this finding may lie in the populations 
investigated, with allergic participants and healthy volun-
teers being included, respectively. It may be easier to con-
dition allergic responses in allergic participants who are 
familiar with the UCS as well as the UCR than to condi-
tion immunostimulation in healthy volunteers for whom 
both UCS and UCR are novel. Secondly, an organism 
might less easily show CR that endanger homeostasis 
 [36] , like an acute systemic inflammatory response, which 
was used as a CR in the immunostimulation study with 
LPS  [25] . In the allergen studies, the CR were not accom-
panied by allergic symptoms  [27, 28] , suggesting that the 
CR was not large enough to disrupt homeostasis.
 Regarding the number of evocation trials needed to 
evoke a CR, one evocation trial appears sufficient when 
conditioning with allergens, insulin injections, and dexa-
methasone  [27–30, 33] . This seems to be in contrast to 
studies using CsA as the UCS; among these, the only 
study that did not find a conditioned effect was the one 
using only one evocation trial  [19] . However, an alterna-
tive explanation for the lack of a CR in this study might 
lie in the 12-day lag between acquisition and evocation. 
Regarding the extinction of CR, more differences be-
tween the UCS used were found. While the extinction of 
conditioned immunosuppression appears to be slow  [22, 
23] , conditioned allergic responses showed signs of ex-
tinction during the second evocation  [27] and condi-
tioned antiallergic responses were extinct after 5 evoca-
tion sessions  [9] .  The relatively faster extinction of the CR 
in the studies conditioning allergic responses compared 
to the immunosuppressive studies may potentially be ex-
plained by the use of single-trial conditioning in the al-
lergen studies in contrast to 4 CS-UCS pairings employed 
by the CsA studies, as there are indications that an in-
crease in the number of acquisition trials results in larger 
CR  [27] . Despite their relevance for the possible clinical 
application of conditioned effects on immune and endo-
crine parameters  [22, 23] , only a few studies have ad-
dressed extinction processes. Future studies should con-
sider including more than one acquisition trial to increase 
the chances of finding a CR and more than one evocation 
trial to explore the possible effects of extinction.
 Regarding the characteristics of the CS, all studies in-
cluded in this review used an olfactory CS, presenting ei-
ther a taste or an odor as a stimulus, finding conditioned 
immune and endocrine effects for both CS. Although 
other types of stimuli have also been used (e.g., visual) 
 [37] in conditioning studies, olfactory CS are used most 
frequently and may be the best choice considering the 
adaptive value of learning the consequences of ingestion 
of certain substances for homeostasis, which is reflected 
in conditioned taste avoidance of the CS  [1, 4, 38] . Con-
ditioned taste avoidance might thus only be the behav-
ioral outcome of a CR that affects the immune and endo-
crine system  [4] . For this reason, assessment of the sub-
jective hedonic qualities of the CS as rated by the subject 
provides additional information on whether or not some 
kind of conditioning has taken place, even in the absence 
of conditioned physiological effects  [25] .
 Concerning the sequence in which the CS and the UCS 
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same time as the UCS (56%)  [3, 19–23, 29, 30, 32] or be-
fore the UCS (38%)  [24, 26–28, 31, 33] ; only one study 
administered the UCS before the CS  [25] . However, when 
the route of administration of the UCS is considered, the 
majority of the studies administered the CS prior to the 
UCS, as UCS administered via the oral route take longer 
to be absorbed and thus ‘sensed’ by the central nervous 
system than UCS administered intravenously. Because 
conditioning theory suggests that the CS should predict 
the occurrence of the UCS, conditioning is theoretically 
expected to be most effective in studies in which the CS is 
presented immediately prior to or together with the UCS 
 [39, 40] . The finding that the only study in this review in 
which the intravenously administered UCS was present-
ed before the CS found no conditioned effects might in-
dicate that in future studies the CS should be adminis-
tered immediately prior to or together with the UCS if 
possible.
 As this review shows that the characteristics of the de-
sign affect the outcome of studies, future articles should 
describe the used study design thoroughly so that addi-
tional factors that determine the effectiveness of condi-
tioning paradigms can be identified. Also, as little is 
known about the phenomenon of responders and nonre-
sponders, it would be useful if researchers would provide 
information on this issue. Moreover, it would be advis-
able to assess possible predictors of responsiveness to 
conditioning at baseline. Lastly, the vast majority of the 
studies reviewed here were conducted in healthy male 
volunteers. Future studies should address less selective 
samples to improve generalizability and provide informa-
tion on possible differences in the conditionability in dif-
ferent groups. 
 As the CS used in the studies reviewed here is an inert 
substance, CR on endocrine and immune outcomes are 
frequently referred to as conditioned or learned placebo 
effects  [1, 4, 7] . They illustrate a close interaction between 
the central nervous system and peripheral functions reg-
ulating homeostasis  [1, 2] . Conditioned pharmacological 
effects show that placebo effects not only affect subjective 
symptoms but can also alter specific peripheral mecha-
nisms that are outside of conscious control  [7] . Thereby, 
they broaden the future clinical possibilities of using pla-
cebo effects in clinical practice. Concrete possibilities for 
clinical applications of placebo effects induced by phar-
macological conditioning have been shown by several 
studies using conditioning protocols as adjunct therapy 
in patients. With this approach, beneficial outcomes have 
been reported in patients suffering from psoriasis  [12] , 
ADHD  [10, 11] , systemic lupus erythematosus  [14] , and 
multiple sclerosis  [13] . The use of conditioning protocols 
as adjunct therapy has the potential to reduce unwanted 
side effects  [35] and might also improve the cost-effec-
tiveness of expensive treatments, as fewer and lower dos-
es of a certain medication may be needed to achieve the 
same clinical results  [12, 13, 23] . Even though there are 
indications that conditioning as an addition to pharma-
cological interventions is effective, complete and long-
term replacement of pharmacological treatments with 
conditioning might not be possible as the effect sizes 
found for CR are small and CR become extinct over time. 
Many of the studies in patient samples have methodolog-
ical shortcomings, such as the lack of placebo control 
groups, which is also the reason why they could not be 
included in this review. Future studies in patients should 
strive to overcome these issues by applying a randomized 
placebo-controlled design, using distinct CS, and mea-
suring biochemical as well as subjective outcomes.
 To summarize our findings, classical conditioning of 
immune and endocrine responses is possible for various 
pharmaceutical substances and has great potential for fu-
ture clinical applications. If future studies would careful-
ly consider characteristics of the study design (i.e., num-
ber of acquisition and evocation trials and type of CS) and 
report about effect sizes, extinction effects, and condi-
tioning responders and nonresponders, this would pro-
vide more insight into the full potential of pharmacolog-
ical conditioning. 
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